
    
      The purpose of this study is to provide Midostaurin (study drug) treatment to newly diagnosed
      FLT3 mutated (ITD or TKD) AML adult patients (18 years or older) eligible for standard
      standard induction (cytarabine + daunorubicin/Idarubicin) and consolidation (cytarabine)
      chemotherapy.
    
  